Frankenfield Christopher James
SEC insider (Form 3/4/5 filer). CIK 0001988344. Chief Financial Officer at Xilio Therapeutics, Inc. (XLO). 24 reported Form 4/5 transactions since Sep 2024; latest on Jan 2, 2026. Located in WALTHAM, MA.
Companies Frankenfield Christopher James has filed insider reports for
- Xilio Therapeutics, Inc. (XLO): Officer, Chief Financial Officer
Frankenfield Christopher James
CIK: 0001988344
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Xilio Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (24 total)
- Jan 2, 2026XLO
Xilio Therapeutics, Inc.
SaleDirect7K shares at avg. $0.64$5K - Jan 1, 2026XLO
Xilio Therapeutics, Inc.
ExerciseDirect19.4K shares- - Dec 31, 2025XLO
Xilio Therapeutics, Inc.
AwardDirectStock Option (right to buy)
668.8K shares- - Nov 21, 2025XLO
Xilio Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
37.3K shares- - Nov 21, 2025XLO
Xilio Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
23.8K shares- - Nov 21, 2025XLO
Xilio Therapeutics, Inc.
AwardDirectStock Option (right to buy)
925K shares- - Nov 21, 2025XLO
Xilio Therapeutics, Inc.
AwardDirectStock Option (right to buy)
155.1K shares- - Nov 21, 2025XLO
Xilio Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
155.1K shares- - Nov 21, 2025XLO
Xilio Therapeutics, Inc.
AwardDirectStock Option (right to buy)
23.8K shares- - Nov 21, 2025XLO
Xilio Therapeutics, Inc.
AwardDirectStock Option (right to buy)
37.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 2, 2026 | XLO Xilio Therapeutics, Inc. | Sale | 7,030 | $0.64 | $4,522 | Direct |
| Jan 1, 2026 | XLO Xilio Therapeutics, Inc. | Exercise | 19,375 | - | $0 | Direct |
| Dec 31, 2025 | XLO Xilio Therapeutics, Inc. | Award Stock Option (right to buy) | 668,789 | - | - | Direct |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc. | Disposition Stock Option (right to buy) | 37,296 | - | - | Direct |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc. | Disposition Stock Option (right to buy) | 23,786 | - | - | Direct |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc. | Award Stock Option (right to buy) | 925,000 | - | - | Direct |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc. | Award Stock Option (right to buy) | 155,090 | - | - | Direct |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc. | Disposition Stock Option (right to buy) | 155,090 | - | - | Direct |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc. | Award Stock Option (right to buy) | 23,786 | - | - | Direct |
| Nov 21, 2025 | XLO Xilio Therapeutics, Inc. | Award Stock Option (right to buy) | 37,296 | - | - | Direct |
1-10 of 24 transactions